김승태 (성균관대학교 의과대학, 삼성서울병원)님 | 한빛사연구자 > 한빛사

성균관대학교 의과대학, 삼성서울병원

CV File

최종업데이트 2025.02.20.

Distinct spatially resolved tumor microenvironment trajectories define benefit from ramucirumab plus pembrolizumab in refractory PD-L1+ gastric cancer
- Cancer Immunol. Res., Nov 18 2025, | https://doi.org/10.1158/2326-6066.CIR-25-0625
- 2025-11
- 한빛사논문
Determinants of Response to Sequential Pembrolizumab with Trastuzumab Plus Platinum/5FU in HER2-positive Gastric Cancer: A Phase II Chemoimmunotherapy Trial
- Clin. Cancer Res., February 17 2025 | https://doi.org/10.1158/1078-0432.CCR-24-3528
- 2025-02
- 의약학
- 한빛사논문
Early immune remodeling steers clinical response to frontline chemoimmunotherapy in advanced gastric cancer
- Cancer Discov., Feb 06 2024, | https://doi.org/10.1158/2159-8290.CD-23-0857
- 2024-02
- 의약학
- 한빛사논문
Oxaliplatin (3 months v 6 months) With 6 Months of Fluoropyrimidine as Adjuvant Therapy in Patients With Stage II/III Colon Cancer: KCSG CO09-07
- J. Clin. Oncol., Published online June 30, 2022. | DOI: 10.1200/JCO.21.02962
- 2022-06
- 의약학
- 한빛사논문
Phase I study of ceralasertib (AZD6738), a novel DNA damage repair agent, in combination with weekly paclitaxel in refractory cancer
- Clin. Cancer Res., Published first May 11, 2021 | https://doi.org/10.1158/1078-0432.CCR-21-0251
- 2021-05
- 의약학
- 한빛사논문
Determinants of Response and Intrinsic Resistance to PD-1 Blockade in Microsatellite Instability-High Gastric Cancer
- Cancer Discov., April 12, 2021 | https://doi.org/10.1158/2159-8290.CD-21-0219
- 2021-04
- 의약학
- 한빛사논문
Comprehensive molecular characterization of gastric cancer patients from phase II second-line ramucirumab plus paclitaxel therapy trial
- Genome Med., Published: 25 January 2021, 13, Article number: 11 | https://doi.org/10.1186/s13073-021-00826-w
- 2021-01
- 의약학
- 한빛사논문
Tumor genomic profiling guides metastatic gastric cancer patients to targeted treatment: The VIKTORY Umbrella Trial
- Cancer Discov., Published OnlineFirst July 17, 2019 | DOI: 10.1158/2159-8290.CD-19-0442
- 2019-07
- 의약학
- 한빛사논문
Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial 
- Ann. Oncol., Volume 30, Issue 5, May 2019, Pages 788-795 | https://doi.org/10.1093/annonc/mdz058
- 2019-05
- 의약학
- 한빛사논문
Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer
- Nat. Med., Published: 16 July 2018 | https://doi.org/10.1038/s41591-018-0101-z
- 2018-07
- 의약학
- 한빛사논문, 상위피인용논문

저자논문

저자논문

저자논문

저자논문

CV 열람하기

연락처 보기